Zalviso™ 15 mcg
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Acute Pain
Conditions
Moderate-to-severe Acute Pain
Trial Timeline
Sep 28, 2016 → May 5, 2017
NCT ID
NCT02662764About Zalviso™ 15 mcg
Zalviso™ 15 mcg is a phase 3 stage product being developed by Talphera for Moderate-to-severe Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02662764. Target conditions include Moderate-to-severe Acute Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02662764 | Phase 3 | Completed |
Competing Products
13 competing products in Moderate-to-severe Acute Pain
Other Products from Talphera
sufentanil sublingual tablet 30 mcgPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCAPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69
sufentanil sublingual 30 mcg tabletPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69